K W Selmaj

Summary

Affiliation: University of Lodz
Country: Poland

Publications

  1. ncbi request reprint [Open trial of the effectiveness of interferon beta 1a (Avonex) in multiple sclerosis. Clinical assessment using motor coordination tests]
    Krzysztof Selmaj
    Klinika Neurologii Uniwersytetu Medycznego w Łodzi
    Neurol Neurochir Pol 37:1163-83. 2003
  2. ncbi request reprint Experimental autoimmune encephalomyelitis: CC chemokine receptor expression by trafficking cells
    Andrzej R Glabinski
    Department of Neurology, Medical University of Lodz, ul Kopcinskiego 22, 90 153, Łódź, Poland
    J Autoimmun 19:175-81. 2002
  3. ncbi request reprint [Bickerstaff's brainstem encephalitis -- an analysis of clinical and MRI findings]
    Tomasz Berkowicz
    Klinika Neurologii, Uniwersytet Medyczny, ul Kopcinskiego 22, 90 153 Łódź
    Neurol Neurochir Pol 40:16-21. 2006
  4. doi request reprint Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
    Krzysztof Selmaj
    Department of Neurology, Medical University of Lodz, Lodz, Poland
    Lancet Neurol 12:756-67. 2013
  5. pmc NCF1 gene and pseudogene pattern: association with parasitic infection and autoimmunity
    Bernhard Greve
    Hertie Institute for Clinical Brain Research, Department of General Neurology, University of Tubingen, Tubingen, Germany
    Malar J 7:251. 2008
  6. ncbi request reprint Suppression of experimental autoimmune encephalomyelitis with a TNF binding protein (TNFbp) correlates with down-regulation of VCAM-1/VLA-4
    K Selmaj
    Department of Neurology, Medical Academy of Lodz, Poland
    Eur J Immunol 28:2035-44. 1998
  7. ncbi request reprint TNF-alpha microinjection upregulates chemokines and chemokine receptors in the central nervous system without inducing leukocyte infiltration
    Andrzej R Glabinski
    Department of Neurology, Medical University of Lodz, Lodz, Poland
    J Interferon Cytokine Res 23:457-66. 2003
  8. ncbi request reprint [Open trial of the effectiveness of interferon beta 1a (Avonex) in the treatment of multiple sclerosis in Poland: MRI results]
    Małgorzata Siger-Zajdel
    Klinika Neurologii Uniwersytetu Medycznego w Łodzi
    Neurol Neurochir Pol 37:1185-97. 2003
  9. ncbi request reprint [Cognitive impairment in multiple sclerosis]
    Iwona Karlińska
    Katedra i Klinika Neurologii, Uniwersytet Medyczny w Łodzi
    Neurol Neurochir Pol 39:125-33. 2005
  10. ncbi request reprint TNF-induced death of adult human oligodendrocytes is mediated by c-jun NH2-terminal kinase-3
    Anna Jurewicz
    Department of Neurology, Medical University of Lodz, Lodz, Poland
    Brain 126:1358-70. 2003

Detail Information

Publications27

  1. ncbi request reprint [Open trial of the effectiveness of interferon beta 1a (Avonex) in multiple sclerosis. Clinical assessment using motor coordination tests]
    Krzysztof Selmaj
    Klinika Neurologii Uniwersytetu Medycznego w Łodzi
    Neurol Neurochir Pol 37:1163-83. 2003
    ..The aim of the study was to evaluate clinical efficacy and safety of interferon beta 1A (Avonex) in the Polish population of remitting-relapsing multiple sclerosis (RR MS) patients...
  2. ncbi request reprint Experimental autoimmune encephalomyelitis: CC chemokine receptor expression by trafficking cells
    Andrzej R Glabinski
    Department of Neurology, Medical University of Lodz, ul Kopcinskiego 22, 90 153, Łódź, Poland
    J Autoimmun 19:175-81. 2002
    ..The principal cells expressing CCR5 were inflammatory cells invading the spinal cord. Our results supported the implication of Th1-associated CCRs in the CNS-specific inflammatory reaction of ChREAE...
  3. ncbi request reprint [Bickerstaff's brainstem encephalitis -- an analysis of clinical and MRI findings]
    Tomasz Berkowicz
    Klinika Neurologii, Uniwersytet Medyczny, ul Kopcinskiego 22, 90 153 Łódź
    Neurol Neurochir Pol 40:16-21. 2006
    ..A special pattern of changes in magnetic resonance imaging (MRI) is characteristic of BBE. Lesions are located mainly in the brainstem. The aim of this paper is to analyze the clinical course and MRI changes in our own cases of BBE...
  4. doi request reprint Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
    Krzysztof Selmaj
    Department of Neurology, Medical University of Lodz, Lodz, Poland
    Lancet Neurol 12:756-67. 2013
    ..We aimed to determine the dose-response relation of siponimod in terms of its effects on brain MRI lesion activity and characterise safety and tolerability in patients with relapsing-remitting multiple sclerosis...
  5. pmc NCF1 gene and pseudogene pattern: association with parasitic infection and autoimmunity
    Bernhard Greve
    Hertie Institute for Clinical Brain Research, Department of General Neurology, University of Tubingen, Tubingen, Germany
    Malar J 7:251. 2008
    ..An individual genomic pattern of ncf1 and its two types of pseudogenes (reflected by the DeltaGT/GTGT ratio) may influence the individual capacity to produce ROI...
  6. ncbi request reprint Suppression of experimental autoimmune encephalomyelitis with a TNF binding protein (TNFbp) correlates with down-regulation of VCAM-1/VLA-4
    K Selmaj
    Department of Neurology, Medical Academy of Lodz, Poland
    Eur J Immunol 28:2035-44. 1998
    ..The findings suggest that TNFbp might prevent EAE development by modulating the expression of VCAM-1 and VLA-4...
  7. ncbi request reprint TNF-alpha microinjection upregulates chemokines and chemokine receptors in the central nervous system without inducing leukocyte infiltration
    Andrzej R Glabinski
    Department of Neurology, Medical University of Lodz, Lodz, Poland
    J Interferon Cytokine Res 23:457-66. 2003
    ..This observation shows that upregulation of chemokines by TNF-alpha is not sufficient to cause accumulation of leukocytes in the CNS parenchyma in both strains of mice...
  8. ncbi request reprint [Open trial of the effectiveness of interferon beta 1a (Avonex) in the treatment of multiple sclerosis in Poland: MRI results]
    Małgorzata Siger-Zajdel
    Klinika Neurologii Uniwersytetu Medycznego w Łodzi
    Neurol Neurochir Pol 37:1185-97. 2003
    ..To assess the effect of interferon-beta 1A (IFNb 1A, Avonex) treatment on magnetic resonance (MR) image in patients with remitting-relapsing multiple sclerosis (RR MS) who participated in the Polish Avonex trial...
  9. ncbi request reprint [Cognitive impairment in multiple sclerosis]
    Iwona Karlińska
    Katedra i Klinika Neurologii, Uniwersytet Medyczny w Łodzi
    Neurol Neurochir Pol 39:125-33. 2005
    ..The results of these correlations showed that an important role in cognitive impairment is related to the total lesion area, the severity of the pathological damage of the normal-appearing brain tissue (NABT), and brain atrophy...
  10. ncbi request reprint TNF-induced death of adult human oligodendrocytes is mediated by c-jun NH2-terminal kinase-3
    Anna Jurewicz
    Department of Neurology, Medical University of Lodz, Lodz, Poland
    Brain 126:1358-70. 2003
    ..This is the first evidence that a JNK-3 isoform is involved in oligodendrocyte death and might have significant importance in designing new molecules to protect hOLs demise in multiple sclerosis...
  11. ncbi request reprint Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial
    Eric J Pappert
    Solstice Neurosciences, Inc, Malvern, Pennsylvania, USA
    Mov Disord 23:510-7. 2008
    ..Mild dry mouth was more frequent with BoNT-B but there were no differences for moderate/severe dry mouth. In this study, both BoNT-A and B were shown to be effective and safe for the treatment of toxin-naive CD subjects...
  12. ncbi request reprint Corpora amylacea from multiple sclerosis brain tissue consists of aggregated neuronal cells
    Krzysztof Selmaj
    Department of Neurology, Medical University of Lodz, Łódź, Poland
    Acta Biochim Pol 55:43-9. 2008
    ..Our data provide evidence supporting the concept that biogenesis of corpora amylacea involves degeneration and aggregation of cells of neuronal origin...
  13. ncbi request reprint Notch3 inhibition in myelin-reactive T cells down-regulates protein kinase C theta and attenuates experimental autoimmune encephalomyelitis
    Maciej Jurynczyk
    Department of Neurology, Medical University of Lodz, 22 Kopcinskiego Street, Lodz, Poland
    J Immunol 180:2634-40. 2008
    ..Thus, selective inhibition of the Notch3 receptor may have important effects on peripheral T cell responses and may offer a new attractive target in treating autoimmune diseases, including multiple sclerosis...
  14. doi request reprint Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis
    Hideki Garren
    Bayhill Therapeutics, Palo Alto, CA 94303, USA
    Ann Neurol 63:611-20. 2008
    ..To evaluate the efficacy and safety of BHT-3009 in relapsing-remitting multiple sclerosis (MS) and to confirm that BHT-3009 causes immune tolerance...
  15. doi request reprint Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial
    F Fazekas
    Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, A 8036 Graz, Austria
    Neurology 71:265-71. 2008
    ..We therefore set out to test two different doses of a new formulation of immunoglobulin termed IGIV-C 10% for suppression of both clinical and MRI disease activity as well as safety...
  16. doi request reprint Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
    Benjamin M Segal
    Department of Neurology, Holtom Garrett Programme in Neuroimmunology, University of Michigan, Ann Arbor, MI 48109 2200, USA
    Lancet Neurol 7:796-804. 2008
    ....
  17. ncbi request reprint MTR discloses subtle changes in the normal-appearing tissue from relatives of patients with MS
    Malgorzata Siger-Zajdel
    Department of Neurology, Medical Academy of Lodz, Poland
    Neurology 58:317-20. 2002
    ..01) and sporadic (p = 0.01) MS had lower NABT MTR histogram peak heights. This study suggests a reduction of truly normal NABT in asymptomatic relatives of patients with MS...
  18. ncbi request reprint Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b
    Chris Polman
    Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    J Neurol 255:480-7. 2008
    ..The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and > or = 2 clinically silent brain MRI lesions...
  19. ncbi request reprint Overcoming failure to repair demyelination in EAE: gamma-secretase inhibition of Notch signaling
    Maciej Jurynczyk
    Department of Neurology, Medical University of Lodz, 22, Kopcinskiego Street, Lodz, 90 153, Poland
    J Neurol Sci 265:5-11. 2008
    ..Our results suggest that inhibiting the non-myelin permissive environment maintained by Notch pathways within the mature CNS offers a new strategy for treating autoimmune demyelination, including MS...
  20. ncbi request reprint Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, CA 94121, USA Email
    Curr Med Res Opin 23:2823-32. 2007
    ....
  21. ncbi request reprint Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis
    Anna Jurewicz
    Department of Neurology, Medical University of Lodz, 22, Kopcinskiego Street, 90 153 Lodz, Poland
    Neurology 68:283-7. 2007
    ..Nogo is a development-related molecule inhibiting axonal regeneration and is a major component of CNS myelin...
  22. ncbi request reprint Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans
    Maria Ban
    University of Cambridge, Department of Clinical Neurosciences, Addenbrooke s Hospital, Hills Road, Cambridge, UK
    J Neuroimmunol 179:108-16. 2006
    ..Association mapping across the candidate genes implicated by these markers in 937 UK trio families revealed modestly associated haplotypes in JAG1 (p=0.019) on chromosome 20p12.2 and POU2AF1 (p=0.003) on chromosome 11q23.1...
  23. ncbi request reprint TRAIL induces death of human oligodendrocytes isolated from adult brain
    Mariola Matysiak
    Department of Neurology, Medical University of Lodz, Poland
    Brain 125:2469-80. 2002
    ..This result may implicate TRAIL as an effector-immune molecule in selective ahOL demise in inflammatory/demyelinating conditions...
  24. ncbi request reprint Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis
    Maciej Jurynczyk
    Department of Neurology, Medical University of Lodz, 22, Kopcinskiego Street, Lodz, 90 153 Poland
    J Neuroimmunol 170:3-10. 2005
    ..Our results suggest that manipulation of the environment associated with Notch activation in the mature CNS provides a promising therapeutic target in MS...
  25. ncbi request reprint TRAIL-induced death of human adult oligodendrocytes is mediated by JNK pathway
    Anna Jurewicz
    Department of Neurology, Medical University of Lodz, Lodz, Poland
    Glia 53:158-66. 2006
    ..These results demonstrate that JNK pathway is critically involved in hOL death induced by TRAIL and might have significant importance in designing new molecules to protect immune-mediated hOLs demise...
  26. ncbi request reprint Treatment with soluble tumor necrosis factor receptor (sTNFR):Fc/p80 fusion protein ameliorates relapsing-remitting experimental autoimmune encephalomyelitis and decreases chemokine expression
    Andrzej R Glabinski
    Department of Neurology, Medical University of Lodz, Poland
    Autoimmunity 37:465-71. 2004
    ..This treatment trial reveals an important function of TNF in the pathogenesis of RR-EAE and propose the mechanism of beneficial action of sTNFR:Fc/p80 in this disease...
  27. ncbi request reprint Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis
    Mariusz Stasiolek
    Department of Neurology, Medical University of Lodz, Lodz, Poland
    Brain 129:1293-305. 2006
    ..These findings suggest functional abnormalities of pDCs in these patients, which might be of importance in the understanding of the development of immune dysregulation in this disease...